Recent Posts

anonymous said:

It’s people with your mentality that are the problem with Phathom

Click to expand...

Blow Me!

Dan Skovronsky saying
“I know it's frustrating for investors and for us perhaps to wait to longer time to get events. But of course, that's great news for patients when the event rates are slower, remembering that this is a head-to-head trial with a drug Trulicity that we already know is active in preventing events”

to analyst question below says it all. Lower expectation please.

“On SURPASS-CVOT, you mentioned it's slipped to 2025. I assume that implies the one interim look has come and gone. And then you're evaluating both noninferiority and superiority.

Would you agree that superiority is really what you need to show here and what's your confidence in achieving that?”

Rick will provide a tik tok rebuttal video “Don’t worry, you lose weight so fast that independent CVOT benefit not required for Mounjaro lmao”

Boo hoo boomer rep, go deliver some sandwiches. None of you really work just collect your paycheck I hope you’re on R&I

anonymous said:

What a joke! I work twice as hard because my Syneos rep barely works and I am pulling their weight. Meanwhile, the Syneos rep gets in the way because of routing and I can't go in their geography (the geography they are not working). Who else is frustrated?

Click to expand...

Sure ya do!